A series of novel peptide-based β-thiolactones were synthesized and assayed for cytotoxicity against several human cancer cell lines, where they showed greater activity than the corresponding β-lactones and β-lactams. Several of the β-thiolactones prepared showed strong inhibitory activity in vitro against human cathepsins B and L.